Complications of polytetrafluoroethylene graft use in middle hepatic vein reconstruction in living donor liver transplantation: a retrospective, single‐centre, long‐term, real‐world experience. (21st January 2021)

• Record Type: Journal Article
• Authors: Woo, Hye Young; Hong, Suk Kyun; Cho, Jae‐Hyung; Lee, Jeong‐Moo; Choi, YoungRok; Yi, Nam‐Joon; Lee, Kwang‐Woong; Suh, Kyung‐Suk
• Is Part Of: Transplant international. Volume 34:Number 3(2021)
• Page Start: 455
• Page End: 464
• Publication Date: 2021-01-21
• Subjects: complication -- graft -- liver transplantation -- living donor -- polytetrafluoroethylene; Transplantation of organs, tissues, etc -- Periodicals; 617.95405
• DOI: 10.1111/tri.13807
• Languages: English
• ISSNs: 0934-0874

Abstract

Summary: In living donor liver transplantation (LDLT) of the right lobe, polytetrafluoroethylene (PTFE) grafts may be used for anterior drainage. This study aimed to determine the risk factors of PTFE graft‐associated complications. Data from patients who underwent LDLT of the right lobe with middle hepatic vein reconstruction using PTFE grafts between January 2005 and December 2012 were retrospectively reviewed. Among 360 patients, PTFE graft‐associated complications occurred in 17 patients (group B) (4.7%); recipients without these complications comprised group A (95.3%). The 1‐, 6‐ and 12‐month patency rates were significantly lower in group B ( P < 0.001, P = 0.002 and P = 0.007). In group B, eight patients (47.1%) required surgical intervention, three patients (17.6%) suffered from infectious complications, and 14 patients (82.4%) experienced PTFE graft migration into the adjacent organs, namely the common bile duct ( n = 3, 17.6%), stomach ( n = 1, 5.9%), duodenum ( n = 5, 29.4%) and jejunum ( n = 5, 29.4%). The proportion of recipients who underwent hepaticojejunostomy, had abdominal adhesions and received interventions in/around the liver after LDLT was higher in group B ( P < 0.001). Although the incidence of PTFE graft‐associated complication is low, close long‐term follow‐up is needed, especially in patients with risk factors.